EnteroBiotix is uniquely positioned to capitalise on the promise of the microbiome as a leading innovator in this field.
Established in March 2017 by Dr James McIlroy, EnteroBiotix is a privately held and well-financed biopharmaceutical company focused on realising the therapeutic potential of the gut microbiome to transform the lives of patients with serious unmet medical needs.
EnteroBiotix is majority owned by a small group of hands-on and committed investors that share a common vision of building a global microbiome-focused pharmaceutical company headquartered in Scotland. Our leadership team, Board of Directors and Expert Advisors have substantial experience and expertise in microbiome science, drug development, CMC and regulatory affairs. We are united by a desire to develop best-in-class medicinal products that will transform the lives of patients suffering from debilitating diseases and infections linked to the gut microbiome.
Our lead assets contain diverse and viable communities of microbiota collected from rigorously screened donors. These therapies represent an entirely new class of medicinal product with the potential to address multiple critical public health needs. To enable our objectives we have established powerful drug development and integrated MHRA-licensed manufacturing capabilities. We have also forged several collaborations with leading institutions and organisations that bolster our internal expertise and capabilities with highly qualified and experienced scientists, acknowledged experts and state-of-the-art research and development facilities.
I am always eager to speak with passionate and driven colleagues that may wish to join us on our missions. If you think you would be a good fit for our team then please email your CV and covering letter to [email protected]